Category Archives: Clean Living

BMJ 2012: 344: 7862 (23rd June)

A couple of sundries. First, we now seem to be quite clear on the pioglitazone-bladder cancer link. From a meta-analysis, the NNH seems to come out as 125, if I’ve worked that out correctly from the figures given. On top … Continue reading

Posted in BMJ, Clean Living, Credits 2012, Diabetes, Infectious Diseases, Medication | Leave a comment

Prescriber 2011 December, Vol 22(23/24)

Low-sodium diets reduce blood pressure in hypertensives by around 5 – 6 mmHg (around 10 in Asians).  However, they increase cholesterol by around 2.5%, and long-term health effects are unknown. Interesting editorial about the recent BMJ meta-analysis of intensive vs. … Continue reading

Posted in Cardiovascular, Clean Living, Diabetes, Endocrinology, Hypertension, Prescriber | Leave a comment

BMJ 2011: 342: 449 – 506 (26th February)

At what age should diabetics start statins?  50 in men and 60 in women, advise two cardiologists in the editorials.  Also, they advise considering their use in men over 55 and women over 65 with multiple risk factors.  Broadening the … Continue reading

Posted in Cardiovascular, Clean Living, Uncategorized | Leave a comment

Synovium 31, Autumn 2010

I usually tell my patients with hip or knee osteoarthritis to stay active, using the logic that a) staying active is A Good Thing generally and b) it will help them avoid the vicious circle of putting on more weight … Continue reading

Posted in Arthritis UK handouts, Clean Living, Joints | Leave a comment

BJGP December 2010: 60(581)

I always thought the Mediterranean diet was just another name for the DASH diet, but how wrong I was. It is, in fact, the new and improved DASH diet, now with added garlic and omega-3-containing fish, and with less sodium. … Continue reading

Posted in Cardiovascular, Clean Living, Gastroenterology, Gout, Rheumatology | Leave a comment

BMJ 2010: 341: 513 – 62 (11th September)

An important point from the first editorial – Stop dishing out medication on the basis of surrogate endpoints hyped up by pharmaceutical companies.  Or, at any rate, think twice and three times about it.  Surrogate endpoints, no matter how promising-looking, are … Continue reading

Posted in BMJ, BMJ 2010, BMJ 341, Cardiovascular, Clean Living, Medication, Neurology, Osteoporosis | Leave a comment